Lipella Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Lipella Pharmaceuticals Inc in the third quarter 2025?
Lipella Pharmaceuticals Inc recorded a cumulative net loss of $-5 million during 12 months ending in the third quarter 2025, resulting in a negative return on equity (ROE) of -208.44%.

Within the Major Pharmaceutical Preparations industry 315 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2025 from 2958 to 3823.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Equity Change	1.97 %	60.92 %	59.26 %	-38.96 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-5	-6	-5	-5	-4
Return On Equity (TTM)	-208.44 %	-216.5 %	-224.03 %	-262.51 %	-192.3 %
LIPO's Total Ranking	# 3823	# 2958	# 3245	# 3200	# 3506
Equity (TTM) in Millions	1	3	4	2	1
Seq. Equity Change	-45.74 %	-32.79 %	112.52 %	31.57 %	-14.37 %
Seq. Net Income Change	-	-	-	-	-

Back to LIPO Management Effectiveness >> LIPO's 5 Years Annual ROE >> Compare LIPO ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 316
Sector	# 661
Overall	# 3823

Return On Equity Statistics
High	Average	Low
-150.11 %	-199.7 %	-262.51 %
(Dec 31 2023)		(Dec 31 2024)

News about Lipella Pharmaceuticals Inc Return on Equity ROE

Lipella Pharmaceuticals: A Promising Drug Pursuit Shrouded in Financial Uncertainty,

Lipella Pharmaceuticals Faces Financial Challenges Amid Promising Drug DevelopmentIn a recent appearance on the Pharmaverse podcast, Michael Chancellor, co-founder of Lipella Pharmaceuticals, discussed the company’s innovative pursuit of new therapeutic solutions, notably the LP-310, aimed at treating oral lichen planus (OLP). However, while the enthusiasm surrounding Lipella s latest drug candidate is palpable, the company s financial situation presents a stark contrast, sparking scrutiny from investors and industry analysts alike.Fiscal reports reveal that Lipella Pharmaceuticals recorded a cumulative net loss of $4 million during the 12 months ending in the third quarter of 2024. This significant deficit translates to a staggering negative return on equity (ROE) of -192.3%. It’s a troubling metric, especially when compared to 305 other firms within the Major Pharmaceutical Preparations industry, which reported a higher return on equity. Only recently, the company s ROE ranking has improved slightly from 3571 to 3506. Nevertheless, this incremental gain does little to mitigate concerns about its ongoing financial viability.

LIPO Annual Return On Equity	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022
Total Equity in Millions	2	3	5	0	0
Y / Y Equity Change	-38.96 %	-32.75 %	-	-	-
Net Income in Millions	-5	-5	-3	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-261.34 %	-146.89 %	-55.56 %	-	-

Back to LIPO Management Effectiveness >> LIPO's 5 Years Annual ROE >> Compare LIPO ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LIPO's' Return on Equity at Yahoo Finance
LIPO's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LIPO's Competitors
Subscribers only: Roe for Lipella Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Equity for LIPO's Customers

Companies with similar Return On Equity at Sep 30 2025, within Healthcare Sector

ROE

Date modified: 2026-09-26T07:42:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.